医学
以兹提米比
PCSK9
叙述性评论
前蛋白转化酶
心理干预
可欣
指南
Evolocumab公司
脂蛋白
胆固醇
生物信息学
内科学
重症监护医学
低密度脂蛋白受体
病理
精神科
载脂蛋白A1
生物
作者
Swagata Patnaik,Matias E. Pollevick,Kyla Lara-Breitinger,Neil J. Stone
标识
DOI:10.1016/j.amjmed.2022.06.018
摘要
Lipid-lowering guidelines emphasize shared decision-making between clinicians and patients, resulting in patients anticipating the degree of response from diet or drug therapy. Challenging for physicians is understanding the sources of variability complicating their management decisions, which include non-adherence, genetic considerations, additional lipid parameters including lipoprotein (a) levels, and rare systemic responses limiting benefits that result in non-responsiveness to monoclonal antibody injection. In this narrative review, we focus on the variability of low-density lipoprotein cholesterol (LDL-C) response to guideline-directed interventions such as statins, ezetimibe, bile acid sequestrants, fibrates, proprotein/convertase subtilisin-kexin type 9 inhibitors, and LDL-C-lowering diets. We hypothesize that the variability in individual lipid responses is multifactorial. We provide an illustrative model with a check list that can be used to identify factors that may be present in the individual patient.
科研通智能强力驱动
Strongly Powered by AbleSci AI